drugset / Trial / NCT00185185

Olmesartan Medoxomil in Atherosclerosis

NCT00185185

Phase 3 Completed 165 enrolled Sankyo Pharma Gmbh
RandomizedParallel-groupDouble-blindTreatment

Summary

This is a study in hypertensive patients with atherosclerosis and increased cardiovascular risk. The efficacy of olmesartan medoxomil on atherosclerosis is measured.

Timeline

Start
2001-11
Primary completion
Completion
2006-02

Drugs

EvaluationDrugModalityDoseRoute
Comparator Atenolol Other / unclassified
Subject Olmesartan medoxomil Unknown
Background Hydrochlorothiazide Unknown